Pharma BD Deal Intelligence
Sanofi to acquire Protein Sciences maker of Flublok recombinant influenza vaccine for $650 million upfront plus $100 million in milestones
Sanofi completes the acquisition of Protein Sciences Corporation and its Flublok recombinant protein-based influenza vaccine platform
Sanofi acquires Protein Sciences gaining FDA-approved Flublok quadrivalent recombinant influenza vaccine and BEST manufacturing platform
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Sanofi acquired Protein Sciences for $650M + $100M milestones for vaccines biotech.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Protein Sciences Corp. (this deal) | 2017 | $650M | 72 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2017 deals · Sanofi SA deals · Infectious Disease deals